KR20040018266A - 질환 치료용 퀴누클리딘 치환된 멀티시클릭 헤테로아릴 - Google Patents
질환 치료용 퀴누클리딘 치환된 멀티시클릭 헤테로아릴 Download PDFInfo
- Publication number
- KR20040018266A KR20040018266A KR10-2003-7016210A KR20037016210A KR20040018266A KR 20040018266 A KR20040018266 A KR 20040018266A KR 20037016210 A KR20037016210 A KR 20037016210A KR 20040018266 A KR20040018266 A KR 20040018266A
- Authority
- KR
- South Korea
- Prior art keywords
- azabicyclo
- oct
- pyridine
- carboxamide
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 62
- 201000010099 disease Diseases 0.000 title claims abstract description 55
- 238000011282 treatment Methods 0.000 title claims description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 195
- 239000000203 mixture Substances 0.000 claims abstract description 138
- 229940079593 drug Drugs 0.000 claims abstract description 105
- 239000003814 drug Substances 0.000 claims abstract description 97
- 150000003839 salts Chemical class 0.000 claims abstract description 51
- -1 thieno [2,3-b] pyridin-2-yl Chemical group 0.000 claims description 268
- 125000000217 alkyl group Chemical group 0.000 claims description 138
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 110
- 125000001424 substituent group Chemical group 0.000 claims description 81
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 74
- 239000002253 acid Substances 0.000 claims description 71
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 68
- 229910052794 bromium Inorganic materials 0.000 claims description 67
- 229910052801 chlorine Inorganic materials 0.000 claims description 66
- 229910052731 fluorine Inorganic materials 0.000 claims description 66
- 229910052757 nitrogen Inorganic materials 0.000 claims description 64
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 59
- UZIYZYPHBOMKBY-UHFFFAOYSA-N furo[3,2-c]pyridine-6-carboxamide Chemical compound C1=NC(C(=O)N)=CC2=C1C=CO2 UZIYZYPHBOMKBY-UHFFFAOYSA-N 0.000 claims description 50
- 229910052740 iodine Inorganic materials 0.000 claims description 48
- TUPZWIXDHKKDRH-UHFFFAOYSA-N thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1=NC(C(=O)N)=CC2=C1C=CS2 TUPZWIXDHKKDRH-UHFFFAOYSA-N 0.000 claims description 48
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 46
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 46
- 208000024891 symptom Diseases 0.000 claims description 45
- CZXIPBIBWCODNX-UHFFFAOYSA-N thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1=NC(C(=O)N)=CC2=C1SC=C2 CZXIPBIBWCODNX-UHFFFAOYSA-N 0.000 claims description 43
- IQQNMLSLUVURHZ-UHFFFAOYSA-N furo[2,3-c]pyridine-5-carboxamide Chemical compound C1=NC(C(=O)N)=CC2=C1OC=C2 IQQNMLSLUVURHZ-UHFFFAOYSA-N 0.000 claims description 40
- 125000003342 alkenyl group Chemical group 0.000 claims description 36
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 33
- 125000000304 alkynyl group Chemical group 0.000 claims description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
- 206010012289 Dementia Diseases 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 201000000980 schizophrenia Diseases 0.000 claims description 23
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 230000005855 radiation Effects 0.000 claims description 21
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 20
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 230000006735 deficit Effects 0.000 claims description 18
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 18
- 208000010877 cognitive disease Diseases 0.000 claims description 17
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 16
- 208000019022 Mood disease Diseases 0.000 claims description 16
- 208000002193 Pain Diseases 0.000 claims description 16
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 16
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 16
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 16
- 208000024827 Alzheimer disease Diseases 0.000 claims description 14
- 208000010412 Glaucoma Diseases 0.000 claims description 14
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 14
- 230000004770 neurodegeneration Effects 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 208000012661 Dyskinesia Diseases 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 13
- 208000028017 Psychotic disease Diseases 0.000 claims description 13
- 230000001149 cognitive effect Effects 0.000 claims description 13
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 12
- 230000000561 anti-psychotic effect Effects 0.000 claims description 12
- 125000001624 naphthyl group Chemical group 0.000 claims description 11
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 11
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims description 11
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 208000028698 Cognitive impairment Diseases 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 9
- 201000010374 Down Syndrome Diseases 0.000 claims description 9
- 208000023105 Huntington disease Diseases 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 9
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 8
- 230000003542 behavioural effect Effects 0.000 claims description 8
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims description 8
- 230000036651 mood Effects 0.000 claims description 8
- 230000000391 smoking effect Effects 0.000 claims description 8
- POPPVIRYGJQIOF-UHFFFAOYSA-N 2-acetyloxyethyl(trimethyl)azanium;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(=O)OCC[N+](C)(C)C.CN1CCCC1C1=CC=CN=C1 POPPVIRYGJQIOF-UHFFFAOYSA-N 0.000 claims description 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 7
- 208000030963 borderline personality disease Diseases 0.000 claims description 7
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 7
- 210000004558 lewy body Anatomy 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 claims description 7
- 230000009529 traumatic brain injury Effects 0.000 claims description 7
- MOUIXKGJJZIQSW-VFZGTOFNSA-N 3-bromo-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2Br MOUIXKGJJZIQSW-VFZGTOFNSA-N 0.000 claims description 6
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 6
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 150000003018 phosphorus compounds Chemical group 0.000 claims description 6
- 208000017194 Affective disease Diseases 0.000 claims description 5
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 5
- 206010020710 Hyperphagia Diseases 0.000 claims description 5
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 5
- 208000034189 Sclerosis Diseases 0.000 claims description 5
- 150000007942 carboxylates Chemical class 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 5
- 235000012631 food intake Nutrition 0.000 claims description 5
- 230000037406 food intake Effects 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- HLURXESIEQDIKV-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2 HLURXESIEQDIKV-BONVTDFDSA-N 0.000 claims description 5
- VSFFJFOPGAUTNI-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C)C2=C1 VSFFJFOPGAUTNI-AWEZNQCLSA-N 0.000 claims description 5
- IPKZCLGGYKRDES-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=C2 IPKZCLGGYKRDES-CYBMUJFWSA-N 0.000 claims description 5
- 235000020830 overeating Nutrition 0.000 claims description 5
- VHGPPUNISVTOTA-ZBEGNZNMSA-N 3-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2C VHGPPUNISVTOTA-ZBEGNZNMSA-N 0.000 claims description 4
- IPKZCLGGYKRDES-ZDUSSCGKSA-N Pha-543613 Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=C2 IPKZCLGGYKRDES-ZDUSSCGKSA-N 0.000 claims description 4
- MVTCXSGPYZCCHC-UHFFFAOYSA-N furo[2,3-c]pyridine-3,5-dicarboxamide Chemical compound O1C=C(C=2C1=CN=C(C=2)C(=O)N)C(=O)N MVTCXSGPYZCCHC-UHFFFAOYSA-N 0.000 claims description 4
- XVMLNQPRWLXRIP-SGTLLEGYSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3-propan-2-ylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=NC=C2OC=C(C(C)C)C2=C1 XVMLNQPRWLXRIP-SGTLLEGYSA-N 0.000 claims description 4
- NQVVSGZEDRARRL-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CN=CC=C2O1 NQVVSGZEDRARRL-BONVTDFDSA-N 0.000 claims description 4
- SZYDYQUYUGMIDV-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=CO2 SZYDYQUYUGMIDV-BONVTDFDSA-N 0.000 claims description 4
- NAINLHWYEAPDSJ-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CC=NC=C2S1 NAINLHWYEAPDSJ-BONVTDFDSA-N 0.000 claims description 4
- OHRZCDCIGLVBCG-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=CS2 OHRZCDCIGLVBCG-BONVTDFDSA-N 0.000 claims description 4
- RVXVUHMZGCOXHD-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-methylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C(OC(C)=C2)C2=C1 RVXVUHMZGCOXHD-AWEZNQCLSA-N 0.000 claims description 4
- NIKKRPJTQPOEOO-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(CC)C2=C1 NIKKRPJTQPOEOO-HNNXBMFYSA-N 0.000 claims description 4
- VHWVJYZANUDUMS-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-propan-2-ylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C(C)C)C2=C1 VHWVJYZANUDUMS-INIZCTEOSA-N 0.000 claims description 4
- BDVPNSZTMSWXJW-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-2-carboxamide Chemical compound N1=CC=C2OC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 BDVPNSZTMSWXJW-LBPRGKRZSA-N 0.000 claims description 4
- YMZFSPQBWIIQLA-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CO2 YMZFSPQBWIIQLA-ZDUSSCGKSA-N 0.000 claims description 4
- ZSGZDXFSNNPGIH-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-2-carboxamide Chemical compound C1=NC=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 ZSGZDXFSNNPGIH-LBPRGKRZSA-N 0.000 claims description 4
- NJNIZJCRCANYGV-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1SC=C2 NJNIZJCRCANYGV-ZDUSSCGKSA-N 0.000 claims description 4
- CKZPWHBWHVGFPO-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CS2 CKZPWHBWHVGFPO-ZDUSSCGKSA-N 0.000 claims description 4
- RVXVUHMZGCOXHD-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2-methylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C(OC(C)=C2)C2=C1 RVXVUHMZGCOXHD-CQSZACIVSA-N 0.000 claims description 4
- NIKKRPJTQPOEOO-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2OC=C(CC)C2=C1 NIKKRPJTQPOEOO-OAHLLOKOSA-N 0.000 claims description 4
- YMZFSPQBWIIQLA-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CO2 YMZFSPQBWIIQLA-CYBMUJFWSA-N 0.000 claims description 4
- NJNIZJCRCANYGV-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1SC=C2 NJNIZJCRCANYGV-CYBMUJFWSA-N 0.000 claims description 4
- GSIWUKSQASDQRX-UHFFFAOYSA-N thieno[3,2-c]pyridine-2,6-dicarboxamide Chemical compound NC(=O)c1cc2cnc(cc2s1)C(N)=O GSIWUKSQASDQRX-UHFFFAOYSA-N 0.000 claims description 4
- YOXRCBPWSPDOQS-ZBEGNZNMSA-N 2-methyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC(C)=C2 YOXRCBPWSPDOQS-ZBEGNZNMSA-N 0.000 claims description 3
- IFWAAKADLPKOJB-GTNSWQLSSA-N 3-ethyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=NC=C2OC=C(CC)C2=C1 IFWAAKADLPKOJB-GTNSWQLSSA-N 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 3
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- PAYJWQZDXBKDIP-UHFFFAOYSA-N furo[3,2-c]pyridine-2,6-dicarboxamide Chemical compound O1C(=CC=2C=NC(=CC=21)C(=O)N)C(=O)N PAYJWQZDXBKDIP-UHFFFAOYSA-N 0.000 claims description 3
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- ALCVTORFSPUAIE-BUXKBTBVSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzofuro[3,2-c]pyridine-3-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C1=CC=CC=C1O2 ALCVTORFSPUAIE-BUXKBTBVSA-N 0.000 claims description 3
- ZNDMIWBPVKVUMQ-BUXKBTBVSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[2,3-c]pyridine-3-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC(C2=CC=CC=C2S2)=C2C=N1 ZNDMIWBPVKVUMQ-BUXKBTBVSA-N 0.000 claims description 3
- POEAWSFIYJPHLM-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,4-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CSC=C2C=N1 POEAWSFIYJPHLM-BONVTDFDSA-N 0.000 claims description 3
- JZLHKFBLZXCFNR-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(Br)C2=C1 JZLHKFBLZXCFNR-ZDUSSCGKSA-N 0.000 claims description 3
- KYCAUWHYDUAAJT-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[2,3-c]pyridine-3-carboxamide Chemical compound S1C2=CC=CC=C2C2=C1C=NC(C(N[C@@H]1C3CCN(CC3)C1)=O)=C2 KYCAUWHYDUAAJT-INIZCTEOSA-N 0.000 claims description 3
- SHNXADNAVHWLIZ-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-6-carboxamide Chemical compound C1=C2C=CSC2=NC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 SHNXADNAVHWLIZ-ZDUSSCGKSA-N 0.000 claims description 3
- OJHDSYCOAYLDKX-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-2-carboxamide Chemical compound C1=CC=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=N1 OJHDSYCOAYLDKX-LBPRGKRZSA-N 0.000 claims description 3
- FSWJILNACZEMQN-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,4-c]pyridine-6-carboxamide Chemical compound C=1C2=CSC=C2C=NC=1C(=O)N[C@@H]1C(CC2)CCN2C1 FSWJILNACZEMQN-AWEZNQCLSA-N 0.000 claims description 3
- JZLHKFBLZXCFNR-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-bromothieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2SC=C(Br)C2=C1 JZLHKFBLZXCFNR-CYBMUJFWSA-N 0.000 claims description 3
- VSFFJFOPGAUTNI-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-methylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2OC=C(C)C2=C1 VSFFJFOPGAUTNI-CQSZACIVSA-N 0.000 claims description 3
- ZSGKCMMGDSDZDP-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzofuro[3,2-c]pyridine-3-carboxamide Chemical compound O1C2=CC=CC=C2C(C=N2)=C1C=C2C(=O)N[C@H]1C(CC2)CCN2C1 ZSGKCMMGDSDZDP-MRXNPFEDSA-N 0.000 claims description 3
- KYCAUWHYDUAAJT-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[2,3-c]pyridine-3-carboxamide Chemical compound S1C2=CC=CC=C2C2=C1C=NC(C(N[C@H]1C3CCN(CC3)C1)=O)=C2 KYCAUWHYDUAAJT-MRXNPFEDSA-N 0.000 claims description 3
- BDVPNSZTMSWXJW-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-2-carboxamide Chemical compound N1=CC=C2OC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 BDVPNSZTMSWXJW-GFCCVEGCSA-N 0.000 claims description 3
- SHNXADNAVHWLIZ-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-6-carboxamide Chemical compound C1=C2C=CSC2=NC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 SHNXADNAVHWLIZ-CYBMUJFWSA-N 0.000 claims description 3
- ZSGZDXFSNNPGIH-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-2-carboxamide Chemical compound C1=NC=C2SC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 ZSGZDXFSNNPGIH-GFCCVEGCSA-N 0.000 claims description 3
- CKZPWHBWHVGFPO-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CS2 CKZPWHBWHVGFPO-CYBMUJFWSA-N 0.000 claims description 3
- FSWJILNACZEMQN-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,4-c]pyridine-6-carboxamide Chemical compound C=1C2=CSC=C2C=NC=1C(=O)N[C@H]1C(CC2)CCN2C1 FSWJILNACZEMQN-CQSZACIVSA-N 0.000 claims description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 230000005586 smoking cessation Effects 0.000 claims description 3
- LCXAXDWXTAXZBD-UHFFFAOYSA-N thieno[2,3-c]pyridine-3,5-dicarboxamide Chemical compound NC(=O)c1csc2cnc(cc12)C(N)=O LCXAXDWXTAXZBD-UHFFFAOYSA-N 0.000 claims description 3
- VZGLFCZPBUXNLF-VFZGTOFNSA-N 2-chloro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(Cl)O2 VZGLFCZPBUXNLF-VFZGTOFNSA-N 0.000 claims description 2
- KKDLSBYVIGWZPQ-VFZGTOFNSA-N 2-chloro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(Cl)S2 KKDLSBYVIGWZPQ-VFZGTOFNSA-N 0.000 claims description 2
- SMWKYNIVPRSPEI-GTNSWQLSSA-N 2-ethenyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C=C)S2 SMWKYNIVPRSPEI-GTNSWQLSSA-N 0.000 claims description 2
- CUYKQIWIGONQTQ-GTNSWQLSSA-N 2-ethynyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C#C)S2 CUYKQIWIGONQTQ-GTNSWQLSSA-N 0.000 claims description 2
- JGFYKIDATWZAGZ-VFZGTOFNSA-N 2-fluoro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(F)O2 JGFYKIDATWZAGZ-VFZGTOFNSA-N 0.000 claims description 2
- SBLYMEZKDSJLKQ-VFZGTOFNSA-N 2-fluoro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(F)S2 SBLYMEZKDSJLKQ-VFZGTOFNSA-N 0.000 claims description 2
- SHIQKQJQJYXFDM-QFYYESIMSA-N 2-formyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C=O)S2 SHIQKQJQJYXFDM-QFYYESIMSA-N 0.000 claims description 2
- WLQCDGAETPDAGB-VFZGTOFNSA-N 3-chloro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2Cl WLQCDGAETPDAGB-VFZGTOFNSA-N 0.000 claims description 2
- GMONOBUIBYANSG-QFYYESIMSA-N 3-cyano-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C#N GMONOBUIBYANSG-QFYYESIMSA-N 0.000 claims description 2
- ZAYDLIOJGLVYGO-GTNSWQLSSA-N 3-ethenyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C=C ZAYDLIOJGLVYGO-GTNSWQLSSA-N 0.000 claims description 2
- BHRKTLYJYRKMHF-VFZGTOFNSA-N 3-fluoro-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2F BHRKTLYJYRKMHF-VFZGTOFNSA-N 0.000 claims description 2
- GTNFVZBVQLFKQY-VFZGTOFNSA-N 5-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[2,3-c]pyridine-3-carboxylic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2C(O)=O GTNFVZBVQLFKQY-VFZGTOFNSA-N 0.000 claims description 2
- GDCGSOGYDOFTMI-ZDUSSCGKSA-N 5-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[2,3-c]pyridine-3-carboxylic acid Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C(=O)O)C2=C1 GDCGSOGYDOFTMI-ZDUSSCGKSA-N 0.000 claims description 2
- CCWGCCFAVGYNDJ-ZDUSSCGKSA-N 5-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]thieno[2,3-c]pyridine-3-carboxylic acid Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(C(=O)O)C2=C1 CCWGCCFAVGYNDJ-ZDUSSCGKSA-N 0.000 claims description 2
- HZMYJKJXRQCLOD-LBPRGKRZSA-N 6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[3,2-c]pyridine-2-carboxylic acid Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C(=O)O)OC2=C1 HZMYJKJXRQCLOD-LBPRGKRZSA-N 0.000 claims description 2
- FWHDJQWQNIOWKD-LBPRGKRZSA-N 6-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]thieno[3,2-c]pyridine-2-carboxylic acid Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C(=O)O)SC2=C1 FWHDJQWQNIOWKD-LBPRGKRZSA-N 0.000 claims description 2
- OKJUGSGVLGUIFP-AWEZNQCLSA-N C1CN2CCC1[C@H](C2)N3C=CC4=C(COC4=C3)N5C=CN=N5 Chemical compound C1CN2CCC1[C@H](C2)N3C=CC4=C(COC4=C3)N5C=CN=N5 OKJUGSGVLGUIFP-AWEZNQCLSA-N 0.000 claims description 2
- UFGIDQVWKGWGRO-AWEZNQCLSA-N C1CN2CCC1[C@H](C2)N3C=CC4=C(COC4=C3)N5C=NC=N5 Chemical compound C1CN2CCC1[C@H](C2)N3C=CC4=C(COC4=C3)N5C=NC=N5 UFGIDQVWKGWGRO-AWEZNQCLSA-N 0.000 claims description 2
- 208000024571 Pick disease Diseases 0.000 claims description 2
- 230000008482 dysregulation Effects 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- FDRCUBQXQOHXTG-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3-sulfanylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2S FDRCUBQXQOHXTG-VFZGTOFNSA-N 0.000 claims description 2
- ZIDUDESSRYFLPU-BUXKBTBVSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[3,2-c]pyridine-3-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C1=CC=CC=C1S2 ZIDUDESSRYFLPU-BUXKBTBVSA-N 0.000 claims description 2
- MWXFWIANVDHCBP-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CC=NC=C2O1 MWXFWIANVDHCBP-BONVTDFDSA-N 0.000 claims description 2
- APXXZFYJXUHKNX-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[3,4-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=COC=C2C=N1 APXXZFYJXUHKNX-BONVTDFDSA-N 0.000 claims description 2
- SZCUXTZRWDJLQZ-HZMBPMFUSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CC=CN=C2S1 SZCUXTZRWDJLQZ-HZMBPMFUSA-N 0.000 claims description 2
- XQEFNJASUQFISC-HZMBPMFUSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CN=C(SC=C2)C2=C1 XQEFNJASUQFISC-HZMBPMFUSA-N 0.000 claims description 2
- XGEIUDHYUFOLGP-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CN=C(C=CS2)C2=C1 XGEIUDHYUFOLGP-BONVTDFDSA-N 0.000 claims description 2
- XVKYYUUVAFBGBX-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CN=CC=C2S1 XVKYYUUVAFBGBX-BONVTDFDSA-N 0.000 claims description 2
- AHGFSCYLKOGUFF-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-(trifluoromethyl)furo[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C(F)(F)F)OC2=C1 AHGFSCYLKOGUFF-LBPRGKRZSA-N 0.000 claims description 2
- OXXZSAFHKNDCIN-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-(trifluoromethyl)thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C(F)(F)F)SC2=C1 OXXZSAFHKNDCIN-LBPRGKRZSA-N 0.000 claims description 2
- OCZPHYJTEFONKI-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-chlorothieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(Cl)SC2=C1 OCZPHYJTEFONKI-LBPRGKRZSA-N 0.000 claims description 2
- LWVHCSQCKPNPJG-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-cyanofuro[3,2-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=C(C#N)O2 LWVHCSQCKPNPJG-AWEZNQCLSA-N 0.000 claims description 2
- IESDNJYVPZVDJR-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-ethenylthieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C=C)SC2=C1 IESDNJYVPZVDJR-HNNXBMFYSA-N 0.000 claims description 2
- TXSHFKFYDBKQKL-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-ethynylthieno[3,2-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=C(C#C)S2 TXSHFKFYDBKQKL-HNNXBMFYSA-N 0.000 claims description 2
- ULMXATWHDSQJOF-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-fluorofuro[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(F)OC2=C1 ULMXATWHDSQJOF-LBPRGKRZSA-N 0.000 claims description 2
- QQFLZTVCTNGWCQ-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-fluorothieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(F)SC2=C1 QQFLZTVCTNGWCQ-LBPRGKRZSA-N 0.000 claims description 2
- UYEVTNKCLBSBCI-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-formylthieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C=O)SC2=C1 UYEVTNKCLBSBCI-AWEZNQCLSA-N 0.000 claims description 2
- CMDDJPYGEIMNOX-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-prop-1-ynylthieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(C#CC)SC2=C1 CMDDJPYGEIMNOX-INIZCTEOSA-N 0.000 claims description 2
- KBRLIPRWHKIQFC-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-sulfanylthieno[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(S)SC2=C1 KBRLIPRWHKIQFC-LBPRGKRZSA-N 0.000 claims description 2
- KAIMJRMQKIFTLJ-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(trifluoromethyl)furo[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(C(F)(F)F)C2=C1 KAIMJRMQKIFTLJ-ZDUSSCGKSA-N 0.000 claims description 2
- UUQSMBNSSYAEBK-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(trifluoromethyl)thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(C(F)(F)F)C2=C1 UUQSMBNSSYAEBK-ZDUSSCGKSA-N 0.000 claims description 2
- USCXOKXKBVJNGO-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-chlorothieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(Cl)C2=C1 USCXOKXKBVJNGO-ZDUSSCGKSA-N 0.000 claims description 2
- LUEXKOGGZCIXMK-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-cyanothieno[2,3-c]pyridine-5-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1SC=C2C#N LUEXKOGGZCIXMK-AWEZNQCLSA-N 0.000 claims description 2
- NITXMZIWGNWXJN-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethynylthieno[2,3-c]pyridine-5-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1SC=C2C#C NITXMZIWGNWXJN-HNNXBMFYSA-N 0.000 claims description 2
- SZHVWEBGUSKQAP-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-fluorothieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(F)C2=C1 SZHVWEBGUSKQAP-ZDUSSCGKSA-N 0.000 claims description 2
- SQQWAXFLSKVQHZ-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-formylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(C=O)C2=C1 SQQWAXFLSKVQHZ-AWEZNQCLSA-N 0.000 claims description 2
- UEVVMXZSVXHGBL-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-prop-1-ynylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(C#CC)C2=C1 UEVVMXZSVXHGBL-INIZCTEOSA-N 0.000 claims description 2
- HBKBYUHWEDDTDO-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-sulfanylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(S)C2=C1 HBKBYUHWEDDTDO-LBPRGKRZSA-N 0.000 claims description 2
- ZSGKCMMGDSDZDP-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzofuro[3,2-c]pyridine-3-carboxamide Chemical compound O1C2=CC=CC=C2C(C=N2)=C1C=C2C(=O)N[C@@H]1C(CC2)CCN2C1 ZSGKCMMGDSDZDP-INIZCTEOSA-N 0.000 claims description 2
- JMDKTKWBOZYREH-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[3,2-c]pyridine-3-carboxamide Chemical compound S1C2=CC=CC=C2C(C=N2)=C1C=C2C(=O)N[C@@H]1C(CC2)CCN2C1 JMDKTKWBOZYREH-INIZCTEOSA-N 0.000 claims description 2
- DGAPFHWBXIIYFB-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-b]pyridine-2-carboxamide Chemical compound C1=CN=C2OC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 DGAPFHWBXIIYFB-LBPRGKRZSA-N 0.000 claims description 2
- QRRVGHRZQSUBCR-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-2-carboxamide Chemical compound C1=NC=C2OC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 QRRVGHRZQSUBCR-LBPRGKRZSA-N 0.000 claims description 2
- SVIPJXPWUBBXDN-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,4-c]pyridine-6-carboxamide Chemical compound C=1C2=COC=C2C=NC=1C(=O)N[C@@H]1C(CC2)CCN2C1 SVIPJXPWUBBXDN-AWEZNQCLSA-N 0.000 claims description 2
- ZLAYHELXVXRZHE-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-5-carboxamide Chemical compound N1=C2SC=CC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 ZLAYHELXVXRZHE-ZDUSSCGKSA-N 0.000 claims description 2
- GLSTVJODWGVAMW-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-5-carboxamide Chemical compound C1=C2SC=CC2=NC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 GLSTVJODWGVAMW-ZDUSSCGKSA-N 0.000 claims description 2
- CKBIGORMZMVQRP-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-6-carboxamide Chemical compound N1=C2C=CSC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 CKBIGORMZMVQRP-ZDUSSCGKSA-N 0.000 claims description 2
- GTPGKSNYGZTLQJ-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-2-carboxamide Chemical compound N1=CC=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 GTPGKSNYGZTLQJ-LBPRGKRZSA-N 0.000 claims description 2
- JMDKTKWBOZYREH-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[3,2-c]pyridine-3-carboxamide Chemical compound S1C2=CC=CC=C2C(C=N2)=C1C=C2C(=O)N[C@H]1C(CC2)CCN2C1 JMDKTKWBOZYREH-MRXNPFEDSA-N 0.000 claims description 2
- ZLAYHELXVXRZHE-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-5-carboxamide Chemical compound N1=C2SC=CC2=CC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 ZLAYHELXVXRZHE-CYBMUJFWSA-N 0.000 claims description 2
- OJHDSYCOAYLDKX-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-2-carboxamide Chemical compound C1=CC=C2SC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=N1 OJHDSYCOAYLDKX-GFCCVEGCSA-N 0.000 claims description 2
- GLSTVJODWGVAMW-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-5-carboxamide Chemical compound C1=C2SC=CC2=NC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 GLSTVJODWGVAMW-CYBMUJFWSA-N 0.000 claims description 2
- CKBIGORMZMVQRP-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-6-carboxamide Chemical compound N1=C2C=CSC2=CC(C(N[C@H]2C3CCN(CC3)C2)=O)=C1 CKBIGORMZMVQRP-CYBMUJFWSA-N 0.000 claims description 2
- GTPGKSNYGZTLQJ-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-2-carboxamide Chemical compound N1=CC=C2SC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 GTPGKSNYGZTLQJ-GFCCVEGCSA-N 0.000 claims description 2
- ZBWCOZDGHJCGSC-UHFFFAOYSA-N thieno[3,2-b]pyridine-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=N1 ZBWCOZDGHJCGSC-UHFFFAOYSA-N 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims 4
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 claims 3
- 206010039966 Senile dementia Diseases 0.000 claims 2
- AMRWFRQVCKJNSX-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2 AMRWFRQVCKJNSX-BONVTDFDSA-N 0.000 claims 2
- RPKOWZMAUPGRIA-HZMBPMFUSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(C=CS2)C2=N1 RPKOWZMAUPGRIA-HZMBPMFUSA-N 0.000 claims 2
- VHWVJYZANUDUMS-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-propan-2-ylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NC=C2OC=C(C(C)C)C2=C1 VHWVJYZANUDUMS-MRXNPFEDSA-N 0.000 claims 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- DZLDDLYHKPAWKK-UHFFFAOYSA-N 2-(2-oxopyrrolidin-1-yl)thieno[3,2-c]pyridine-6-carboxamide Chemical compound C=1C=2C=NC(C(=O)N)=CC=2SC=1N1CCCC1=O DZLDDLYHKPAWKK-UHFFFAOYSA-N 0.000 claims 1
- WFMAMKZWRULFIS-VFZGTOFNSA-N 2-bromo-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(Br)S2 WFMAMKZWRULFIS-VFZGTOFNSA-N 0.000 claims 1
- INWMUDAVJZDCIY-GTNSWQLSSA-N 3-ethynyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C#C INWMUDAVJZDCIY-GTNSWQLSSA-N 0.000 claims 1
- JQSSUIQRZOPQLZ-QFYYESIMSA-N 3-formyl-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C=O JQSSUIQRZOPQLZ-QFYYESIMSA-N 0.000 claims 1
- GFMQGLPLXYLYJC-VFZGTOFNSA-N 3-iodo-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2I GFMQGLPLXYLYJC-VFZGTOFNSA-N 0.000 claims 1
- HATNIVPQHPPODQ-VFZGTOFNSA-N 5-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]thieno[2,3-c]pyridine-3-carboxylic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1SC=C2C(O)=O HATNIVPQHPPODQ-VFZGTOFNSA-N 0.000 claims 1
- YMLWSKLMDHVQKB-VFZGTOFNSA-N 6-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]furo[3,2-c]pyridine-2-carboxylic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C(O)=O)O2 YMLWSKLMDHVQKB-VFZGTOFNSA-N 0.000 claims 1
- UEASRLFBOHSXFW-VFZGTOFNSA-N 6-[[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]thieno[3,2-c]pyridine-2-carboxylic acid Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C(O)=O)S2 UEASRLFBOHSXFW-VFZGTOFNSA-N 0.000 claims 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 1
- FEVQFXFENDJDOV-UGSOOPFHSA-N C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5C=CN=C5 Chemical compound C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5C=CN=C5 FEVQFXFENDJDOV-UGSOOPFHSA-N 0.000 claims 1
- ARYGECUJTHLRPC-DJJJIMSYSA-N C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5CCNC(=O)C5 Chemical compound C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5CCNC(=O)C5 ARYGECUJTHLRPC-DJJJIMSYSA-N 0.000 claims 1
- UTWZSOWJXQBTCF-DJJJIMSYSA-N C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5CCOCC5=O Chemical compound C[C@H]1[C@@H](C2CCN1CC2)N3C=CC4=C(COC4=C3)N5CCOCC5=O UTWZSOWJXQBTCF-DJJJIMSYSA-N 0.000 claims 1
- NGOIFLIWDZQUSK-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-1h-pyrrolo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1NC=C2 NGOIFLIWDZQUSK-BONVTDFDSA-N 0.000 claims 1
- KXMPVGDWAMTMMH-SGTLLEGYSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2-prop-1-ynylthieno[3,2-c]pyridine-6-carboxamide Chemical class C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=NC=C2C=C(C#CC)SC2=C1 KXMPVGDWAMTMMH-SGTLLEGYSA-N 0.000 claims 1
- GUPYMTMXCSKCQI-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2-sulfanylthieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(S)S2 GUPYMTMXCSKCQI-VFZGTOFNSA-N 0.000 claims 1
- DAPOUYROVRHYDT-SGTLLEGYSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3-prop-1-ynylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1CN([C@H]2C)CCC1[C@H]2NC(=O)C1=NC=C2SC=C(C#CC)C2=C1 DAPOUYROVRHYDT-SGTLLEGYSA-N 0.000 claims 1
- RISTWJRRDGELMS-BUXKBTBVSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzofuro[2,3-c]pyridine-3-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC(C2=CC=CC=C2O2)=C2C=N1 RISTWJRRDGELMS-BUXKBTBVSA-N 0.000 claims 1
- WHQLQXNZOITJIM-HZMBPMFUSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-b]pyridine-2-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC2=CC=CN=C2O1 WHQLQXNZOITJIM-HZMBPMFUSA-N 0.000 claims 1
- DCGZPTATTXTVRS-BONVTDFDSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C1=CC=C(SC=C2)C2=N1 DCGZPTATTXTVRS-BONVTDFDSA-N 0.000 claims 1
- DFPSNUNFNPWITQ-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1-methylpyrrolo[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2N(C)C=CC2=C1 DFPSNUNFNPWITQ-AWEZNQCLSA-N 0.000 claims 1
- PDGSKMBKOMNHDR-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1h-pyrrolo[2,3-c]pyridine-5-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1NC=C2 PDGSKMBKOMNHDR-AWEZNQCLSA-N 0.000 claims 1
- VTXLFWSHOAIAQR-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-cyanothieno[3,2-c]pyridine-6-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=C(C#N)S2 VTXLFWSHOAIAQR-AWEZNQCLSA-N 0.000 claims 1
- WEWVHODRKIDELE-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-sulfanylfuro[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(S)OC2=C1 WEWVHODRKIDELE-LBPRGKRZSA-N 0.000 claims 1
- VOKHGYRIBDYBEF-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethenylthieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(C=C)C2=C1 VOKHGYRIBDYBEF-HNNXBMFYSA-N 0.000 claims 1
- DCTUPJPSCABRHP-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-methoxyfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C(N=C1OC)=CC2=C1OC=C2 DCTUPJPSCABRHP-ZDUSSCGKSA-N 0.000 claims 1
- PXSUUTRGRAOOHS-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-methylfuro[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C(N=C1C)=CC2=C1OC=C2 PXSUUTRGRAOOHS-AWEZNQCLSA-N 0.000 claims 1
- MZQSJUPWLIOLPC-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzofuro[2,3-c]pyridine-3-carboxamide Chemical compound O1C2=CC=CC=C2C2=C1C=NC(C(N[C@@H]1C3CCN(CC3)C1)=O)=C2 MZQSJUPWLIOLPC-INIZCTEOSA-N 0.000 claims 1
- MRERTYLGKXMNLX-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CN=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 MRERTYLGKXMNLX-LBPRGKRZSA-N 0.000 claims 1
- DGAPFHWBXIIYFB-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-b]pyridine-2-carboxamide Chemical compound C1=CN=C2OC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 DGAPFHWBXIIYFB-GFCCVEGCSA-N 0.000 claims 1
- QRRVGHRZQSUBCR-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-2-carboxamide Chemical compound C1=NC=C2OC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 QRRVGHRZQSUBCR-GFCCVEGCSA-N 0.000 claims 1
- MRERTYLGKXMNLX-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CN=C2SC(C(N[C@H]3C4CCN(CC4)C3)=O)=CC2=C1 MRERTYLGKXMNLX-GFCCVEGCSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 257
- 239000007787 solid Substances 0.000 description 177
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 173
- 238000006243 chemical reaction Methods 0.000 description 132
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 122
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 114
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 109
- 239000000460 chlorine Substances 0.000 description 104
- 239000000243 solution Substances 0.000 description 103
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 94
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 85
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 85
- 235000019439 ethyl acetate Nutrition 0.000 description 85
- 239000012044 organic layer Substances 0.000 description 69
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 67
- 239000003921 oil Substances 0.000 description 60
- 235000019198 oils Nutrition 0.000 description 60
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- 239000010410 layer Substances 0.000 description 46
- 230000000694 effects Effects 0.000 description 44
- 235000002639 sodium chloride Nutrition 0.000 description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 41
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 38
- 229920006395 saturated elastomer Polymers 0.000 description 35
- 238000004587 chromatography analysis Methods 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 239000011734 sodium Substances 0.000 description 31
- 230000008878 coupling Effects 0.000 description 30
- 238000010168 coupling process Methods 0.000 description 30
- 238000005859 coupling reaction Methods 0.000 description 30
- 238000001816 cooling Methods 0.000 description 29
- 235000019441 ethanol Nutrition 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- 229960004756 ethanol Drugs 0.000 description 27
- 239000000463 material Substances 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 24
- 239000000377 silicon dioxide Substances 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 19
- 229960002715 nicotine Drugs 0.000 description 19
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- 238000010898 silica gel chromatography Methods 0.000 description 19
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 230000003935 attention Effects 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 18
- 239000002002 slurry Substances 0.000 description 18
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 17
- 239000000164 antipsychotic agent Substances 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 239000003054 catalyst Substances 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 14
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 239000013058 crude material Substances 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 11
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 229910052763 palladium Inorganic materials 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 241000238876 Acari Species 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 235000011089 carbon dioxide Nutrition 0.000 description 8
- 230000019771 cognition Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 239000000908 ammonium hydroxide Substances 0.000 description 7
- 206010013663 drug dependence Diseases 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 239000011630 iodine Substances 0.000 description 7
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 7
- 230000000698 schizophrenic effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- 239000003693 atypical antipsychotic agent Substances 0.000 description 6
- 229940127236 atypical antipsychotics Drugs 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 230000001713 cholinergic effect Effects 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000019988 mead Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 208000011117 substance-related disease Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000003039 volatile agent Substances 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 206010012218 Delirium Diseases 0.000 description 5
- 206010012239 Delusion Diseases 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 208000022531 anorexia Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 231100000870 cognitive problem Toxicity 0.000 description 5
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 231100000868 delusion Toxicity 0.000 description 5
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000010502 orange oil Substances 0.000 description 5
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- IYWLMYXIUVLLGB-GAGWNIJNSA-N (2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CN2[C@@H](C)[C@H](N)C1CC2 IYWLMYXIUVLLGB-GAGWNIJNSA-N 0.000 description 4
- REUAXQZIRFXQML-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine Chemical class C1CC2C(N)CN1CC2 REUAXQZIRFXQML-UHFFFAOYSA-N 0.000 description 4
- ZKMZPXWMMSBLNO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2C(=O)CN1CC2 ZKMZPXWMMSBLNO-UHFFFAOYSA-N 0.000 description 4
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 4
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- 206010025421 Macule Diseases 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000013016 learning Effects 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 4
- 208000027061 mild cognitive impairment Diseases 0.000 description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- KTEXIXPZKKQNSC-UHFFFAOYSA-N thieno[2,3-b]pyridine-6-carboxamide Chemical compound NC(=O)C1=CC=C2C=CSC2=N1 KTEXIXPZKKQNSC-UHFFFAOYSA-N 0.000 description 4
- REUAXQZIRFXQML-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2[C@@H](N)CN1CC2 REUAXQZIRFXQML-ZETCQYMHSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- HGMKWFMIOFOYOX-UHFFFAOYSA-N 2-formyl-3-methylbutanenitrile;sodium Chemical compound [Na].CC(C)C(C=O)C#N HGMKWFMIOFOYOX-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 208000003443 Unconsciousness Diseases 0.000 description 3
- 208000021017 Weight Gain Diseases 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940005529 antipsychotics Drugs 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 231100000871 behavioral problem Toxicity 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 238000009225 cognitive behavioral therapy Methods 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- 208000011325 dry age related macular degeneration Diseases 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000035474 group of disease Diseases 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 3
- 230000008450 motivation Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- FPXVLCLVAIUGPW-UHFFFAOYSA-N pyridin-3-ylmethyl acetate Chemical compound CC(=O)OCC1=CC=CN=C1 FPXVLCLVAIUGPW-UHFFFAOYSA-N 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
- YSMXJEKOIIULPX-UHFFFAOYSA-N (6-chloro-4-iodo-5-prop-2-enoxypyridin-2-yl)methanol Chemical compound OCC1=CC(I)=C(OCC=C)C(Cl)=N1 YSMXJEKOIIULPX-UHFFFAOYSA-N 0.000 description 2
- MBNMGGKBGCIEGF-UHFFFAOYSA-N 1,1-diethoxypropane Chemical compound CCOC(CC)OCC MBNMGGKBGCIEGF-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- CYXIMHJYXZWMFY-UHFFFAOYSA-N 1-benzofuran-2,3-dicarbaldehyde Chemical compound C1=CC=C2C(C=O)=C(C=O)OC2=C1 CYXIMHJYXZWMFY-UHFFFAOYSA-N 0.000 description 2
- JPYBOGFQEPDJRZ-UHFFFAOYSA-N 2,3-dibromo-1-benzofuran Chemical compound C1=CC=C2C(Br)=C(Br)OC2=C1 JPYBOGFQEPDJRZ-UHFFFAOYSA-N 0.000 description 2
- JYYNAJVZFGKDEQ-UHFFFAOYSA-N 2,4-Dimethylpyridine Chemical compound CC1=CC=NC(C)=C1 JYYNAJVZFGKDEQ-UHFFFAOYSA-N 0.000 description 2
- GMAJNANLBOHCAU-UHFFFAOYSA-N 2,4-dimethyl-5-nitropyridine Chemical compound CC1=CC(C)=C([N+]([O-])=O)C=N1 GMAJNANLBOHCAU-UHFFFAOYSA-N 0.000 description 2
- RKOLKIWJSXSHLV-UHFFFAOYSA-N 2,6-dibromopyridin-3-ol Chemical compound OC1=CC=C(Br)N=C1Br RKOLKIWJSXSHLV-UHFFFAOYSA-N 0.000 description 2
- HVCYBWBFGOWBFT-UHFFFAOYSA-N 2-(1,3-dioxolan-2-yl)-1-benzofuran-3-carbaldehyde Chemical compound O1C2=CC=CC=C2C(C=O)=C1C1OCCO1 HVCYBWBFGOWBFT-UHFFFAOYSA-N 0.000 description 2
- CQSRCIILSKBLOI-UHFFFAOYSA-N 2-(3-bromofuran-2-yl)-1,3-dioxolane Chemical compound C1=COC(C2OCCO2)=C1Br CQSRCIILSKBLOI-UHFFFAOYSA-N 0.000 description 2
- VOLZBNCSKJILIA-UHFFFAOYSA-N 2-(diethoxymethyl)furo[2,3-c]pyridine Chemical compound C1=NC=C2OC(C(OCC)OCC)=CC2=C1 VOLZBNCSKJILIA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NQELPILICRHYOE-UHFFFAOYSA-N 2-chloro-6-(hydroxymethyl)pyridin-3-ol Chemical compound OCC1=CC=C(O)C(Cl)=N1 NQELPILICRHYOE-UHFFFAOYSA-N 0.000 description 2
- KHPAGGHFIDLUMB-UHFFFAOYSA-N 2-chloropyridine-3-carbaldehyde Chemical compound ClC1=NC=CC=C1C=O KHPAGGHFIDLUMB-UHFFFAOYSA-N 0.000 description 2
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- NHPWIWAGVOXDPU-UHFFFAOYSA-N 2-methylidene-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(=C)C2=O NHPWIWAGVOXDPU-UHFFFAOYSA-N 0.000 description 2
- JIZRGGUCOQKGQD-UHFFFAOYSA-N 2-nitrothiophene Chemical compound [O-][N+](=O)C1=CC=CS1 JIZRGGUCOQKGQD-UHFFFAOYSA-N 0.000 description 2
- XJHLNJBEPAUFOD-UHFFFAOYSA-N 3-bromo-1-benzofuran-2-carbaldehyde Chemical compound C1=CC=C2C(Br)=C(C=O)OC2=C1 XJHLNJBEPAUFOD-UHFFFAOYSA-N 0.000 description 2
- KLDLDUZMQGWJEA-UHFFFAOYSA-N 3-bromo-2-(1,3-dioxolan-2-yl)-1-benzofuran Chemical compound O1C2=CC=CC=C2C(Br)=C1C1OCCO1 KLDLDUZMQGWJEA-UHFFFAOYSA-N 0.000 description 2
- MBHHSPMBFVERGP-UHFFFAOYSA-N 3-bromothieno[2,3-c]pyridine-5-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1SC=C2Br MBHHSPMBFVERGP-UHFFFAOYSA-N 0.000 description 2
- NEXUNCTUUDERGR-UHFFFAOYSA-N 3-chloro-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC=CC(Cl)=C1 NEXUNCTUUDERGR-UHFFFAOYSA-N 0.000 description 2
- PWRBCZZQRRPXAB-UHFFFAOYSA-N 3-chloropyridine Chemical compound ClC1=CC=CN=C1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 description 2
- GXWYGAIVEGCARB-UHFFFAOYSA-N 3-ethylfuro[2,3-c]pyridine-5-carboxylic acid Chemical compound N1=C(C(O)=O)C=C2C(CC)=COC2=C1 GXWYGAIVEGCARB-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- BBCPUHYBMUPBIQ-UHFFFAOYSA-N 5,7-dibromo-2-(diethoxymethyl)furo[2,3-c]pyridine Chemical compound BrC1=NC(Br)=C2OC(C(OCC)OCC)=CC2=C1 BBCPUHYBMUPBIQ-UHFFFAOYSA-N 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 101000783401 Bungarus multicinctus Alpha-bungarotoxin Proteins 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 102100024452 DNA-directed RNA polymerase III subunit RPC1 Human genes 0.000 description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 241001539473 Euphoria Species 0.000 description 2
- 206010015535 Euphoric mood Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 101000689002 Homo sapiens DNA-directed RNA polymerase III subunit RPC1 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 2
- NZMHBPQNKRGLGA-UHFFFAOYSA-N [1]benzofuro[2,3-c]pyridine-3-carboxamide Chemical compound O1C2=CC=CC=C2C2=C1C=NC(C(=O)N)=C2 NZMHBPQNKRGLGA-UHFFFAOYSA-N 0.000 description 2
- NHANKJDOPVCXFZ-UHFFFAOYSA-N [1]benzothiolo[2,3-c]pyridine-3-carboxamide Chemical compound S1C2=CC=CC=C2C2=C1C=NC(C(=O)N)=C2 NHANKJDOPVCXFZ-UHFFFAOYSA-N 0.000 description 2
- BYLMMOUGBBLSMY-UHFFFAOYSA-N [1]benzothiolo[2,3-c]pyridine-3-carboxylic acid Chemical compound S1C2=CC=CC=C2C2=C1C=NC(C(=O)O)=C2 BYLMMOUGBBLSMY-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 208000013404 behavioral symptom Diseases 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical class OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000003857 carboxamides Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical group CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- FRAKJSUXVQJONI-UHFFFAOYSA-N ethyl furo[2,3-b]pyridine-2-carboxylate Chemical compound C1=CN=C2OC(C(=O)OCC)=CC2=C1 FRAKJSUXVQJONI-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- AHIXHWRUDZFHEZ-UHFFFAOYSA-N furan-2,3-dicarbaldehyde Chemical compound O=CC=1C=COC=1C=O AHIXHWRUDZFHEZ-UHFFFAOYSA-N 0.000 description 2
- IZLZCXOWFDCZLD-UHFFFAOYSA-N furo[2,3-b]pyridine-2-carboxylic acid Chemical compound C1=CN=C2OC(C(=O)O)=CC2=C1 IZLZCXOWFDCZLD-UHFFFAOYSA-N 0.000 description 2
- WMPIDXCJMDIDQY-UHFFFAOYSA-N furo[2,3-c]pyridine-2-carboxylic acid Chemical compound C1=NC=C2OC(C(=O)O)=CC2=C1 WMPIDXCJMDIDQY-UHFFFAOYSA-N 0.000 description 2
- LKXRQBNEOKIHRW-UHFFFAOYSA-N furo[2,3-c]pyridine-5-carbaldehyde Chemical compound C1=NC(C=O)=CC2=C1OC=C2 LKXRQBNEOKIHRW-UHFFFAOYSA-N 0.000 description 2
- BEVAEUJOJMQCIU-UHFFFAOYSA-N furo[2,3-c]pyridine-5-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1OC=C2 BEVAEUJOJMQCIU-UHFFFAOYSA-N 0.000 description 2
- GBJNZGDNTWILNB-UHFFFAOYSA-N furo[3,2-c]pyridine-2-carboxamide Chemical compound N1=CC=C2OC(C(=O)N)=CC2=C1 GBJNZGDNTWILNB-UHFFFAOYSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical group C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 2
- 229960000300 mesoridazine Drugs 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- HXPFPHOMAVLKKD-UHFFFAOYSA-N methyl 3-bromothieno[2,3-c]pyridine-5-carboxylate Chemical compound C1=NC(C(=O)OC)=CC2=C1SC=C2Br HXPFPHOMAVLKKD-UHFFFAOYSA-N 0.000 description 2
- OMAYNBSQUIYKJC-UHFFFAOYSA-N methyl [1]benzothiolo[2,3-c]pyridine-3-carboxylate Chemical compound S1C2=CC=CC=C2C2=C1C=NC(C(=O)OC)=C2 OMAYNBSQUIYKJC-UHFFFAOYSA-N 0.000 description 2
- HAAMRBSFJYFWFW-UHFFFAOYSA-N methyl thieno[3,2-c]pyridine-2-carboxylate Chemical compound N1=CC=C2SC(C(=O)OC)=CC2=C1 HAAMRBSFJYFWFW-UHFFFAOYSA-N 0.000 description 2
- KQQNBNAMXWPKGP-UHFFFAOYSA-N methyl thieno[3,2-c]pyridine-6-carboxylate Chemical compound C1=NC(C(=O)OC)=CC2=C1C=CS2 KQQNBNAMXWPKGP-UHFFFAOYSA-N 0.000 description 2
- OAVYDSCRGZINNE-UHFFFAOYSA-N methyl thieno[3,4-c]pyridine-6-carboxylate Chemical compound C1=NC(C(=O)OC)=CC2=CSC=C21 OAVYDSCRGZINNE-UHFFFAOYSA-N 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RXGHULSMJIVVTA-UHFFFAOYSA-N thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CN=C2SC(C(=O)N)=CC2=C1 RXGHULSMJIVVTA-UHFFFAOYSA-N 0.000 description 2
- MJUWERVDNLIFQL-UHFFFAOYSA-N thieno[2,3-b]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CSC2=N1 MJUWERVDNLIFQL-UHFFFAOYSA-N 0.000 description 2
- CDAPZSKCTPHSJW-UHFFFAOYSA-N thieno[3,4-c]pyridine-6-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=CSC=C21 CDAPZSKCTPHSJW-UHFFFAOYSA-N 0.000 description 2
- GLQWRXYOTXRDNH-UHFFFAOYSA-N thiophen-2-amine Chemical compound NC1=CC=CS1 GLQWRXYOTXRDNH-UHFFFAOYSA-N 0.000 description 2
- GCYSRLXIEWTZNM-UHFFFAOYSA-N thiophene-3,4-dicarbaldehyde Chemical compound O=CC1=CSC=C1C=O GCYSRLXIEWTZNM-UHFFFAOYSA-N 0.000 description 2
- JSLBLMYJYPZTEB-UHFFFAOYSA-N thiophene-3,4-dicarbonitrile Chemical compound N#CC1=CSC=C1C#N JSLBLMYJYPZTEB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 125000005500 uronium group Chemical group 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- VJENICOVWOKEGT-UHFFFAOYSA-N (2-trimethylsilylfuro[2,3-c]pyridin-5-yl)methanol Chemical compound OCC1=NC=C2OC([Si](C)(C)C)=CC2=C1 VJENICOVWOKEGT-UHFFFAOYSA-N 0.000 description 1
- STZHBULOYDCZET-KLXURFKVSA-N (3r)-1-azabicyclo[2.2.2]octan-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CC2[C@@H](N)CN1CC2 STZHBULOYDCZET-KLXURFKVSA-N 0.000 description 1
- REUAXQZIRFXQML-SSDOTTSWSA-N (3s)-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2[C@H](N)CN1CC2 REUAXQZIRFXQML-SSDOTTSWSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- IIPJFASIZVDONL-UHFFFAOYSA-N (7-chloro-2-trimethylsilylfuro[2,3-c]pyridin-5-yl)methanol Chemical compound OCC1=NC(Cl)=C2OC([Si](C)(C)C)=CC2=C1 IIPJFASIZVDONL-UHFFFAOYSA-N 0.000 description 1
- MEUAAEMCZUPORO-LRSHZYOCSA-N (9z)-n,n-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide;dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl.C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 MEUAAEMCZUPORO-LRSHZYOCSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 description 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 description 1
- FEWLNYSYJNLUOO-UHFFFAOYSA-N 1-Piperidinecarboxaldehyde Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 description 1
- STZHBULOYDCZET-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine;hydron;dichloride Chemical compound Cl.Cl.C1CC2C(N)CN1CC2 STZHBULOYDCZET-UHFFFAOYSA-N 0.000 description 1
- VTZUYVQTGCJXFL-UHFFFAOYSA-N 1-benzothiophene-2,3-dicarbaldehyde Chemical compound C1=CC=C2C(C=O)=C(C=O)SC2=C1 VTZUYVQTGCJXFL-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical class CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OZJHMIHJOVLYDQ-UHFFFAOYSA-N 1-methylpyrrolo[2,3-c]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=NC=C2N(C)C=CC2=C1 OZJHMIHJOVLYDQ-UHFFFAOYSA-N 0.000 description 1
- MOQKFCFVTVIJJS-UHFFFAOYSA-N 2,4-dimethyl-3-nitropyridine Chemical compound CC1=CC=NC(C)=C1[N+]([O-])=O MOQKFCFVTVIJJS-UHFFFAOYSA-N 0.000 description 1
- IQPNPNUASXZTTO-UHFFFAOYSA-N 2-(1,3-dioxolan-2-yl)-1h-pyrrole Chemical compound O1CCOC1C1=CC=CN1 IQPNPNUASXZTTO-UHFFFAOYSA-N 0.000 description 1
- MRUJSTYNKVSMNY-UHFFFAOYSA-N 2-(1,3-dioxolan-2-yl)-4-methyl-5-nitropyridine Chemical compound C1=C([N+]([O-])=O)C(C)=CC(C2OCCO2)=N1 MRUJSTYNKVSMNY-UHFFFAOYSA-N 0.000 description 1
- ZTGNCLWZRMCVGU-UHFFFAOYSA-N 2-(2-oxopyrrolidin-1-yl)furo[2,3-c]pyridine-5-carboxamide Chemical compound O1C=2C=NC(C(=O)N)=CC=2C=C1N1CCCC1=O ZTGNCLWZRMCVGU-UHFFFAOYSA-N 0.000 description 1
- PRVUTBMNNPPEEU-UHFFFAOYSA-N 2-(diethoxymethyl)furo[3,2-c]pyridine Chemical compound N1=CC=C2OC(C(OCC)OCC)=CC2=C1 PRVUTBMNNPPEEU-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- VRHJBWUIWQOFLF-WLHGVMLRSA-N 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 VRHJBWUIWQOFLF-WLHGVMLRSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical group N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- YKHQFTANTNMYPP-UHFFFAOYSA-N 2-bromopyridin-3-ol Chemical compound OC1=CC=CN=C1Br YKHQFTANTNMYPP-UHFFFAOYSA-N 0.000 description 1
- UPUKXPTXCGNQJR-UHFFFAOYSA-N 2-chloro-6-(hydroxymethyl)-4-(2-trimethylsilylethynyl)pyridin-3-ol Chemical compound C[Si](C)(C)C#CC1=CC(CO)=NC(Cl)=C1O UPUKXPTXCGNQJR-UHFFFAOYSA-N 0.000 description 1
- RSOPTYAZDFSMTN-UHFFFAOYSA-N 2-chloropyridin-3-ol Chemical compound OC1=CC=CN=C1Cl RSOPTYAZDFSMTN-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- GHOQDSVTOLDBAH-QFYYESIMSA-N 2-cyano-n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C#N)S2 GHOQDSVTOLDBAH-QFYYESIMSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- IKCQWKJZLSDDSS-UHFFFAOYSA-N 2-formyloxyethyl formate Chemical compound O=COCCOC=O IKCQWKJZLSDDSS-UHFFFAOYSA-N 0.000 description 1
- JQEZLSUFDXSIEK-UHFFFAOYSA-N 2-hydroxy-2-(phenylmethoxycarbonylamino)acetic acid Chemical compound OC(=O)C(O)NC(=O)OCC1=CC=CC=C1 JQEZLSUFDXSIEK-UHFFFAOYSA-N 0.000 description 1
- IYWLMYXIUVLLGB-UHFFFAOYSA-N 2-methyl-1-azabicyclo[2.2.2]octan-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CN2C(C)C(N)C1CC2 IYWLMYXIUVLLGB-UHFFFAOYSA-N 0.000 description 1
- LGOHLIRGPFPGKT-UHFFFAOYSA-N 2-methyl-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(C)C2=O LGOHLIRGPFPGKT-UHFFFAOYSA-N 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- WGTNAUBLJLWMAP-UHFFFAOYSA-N 2-methylidene-1-azabicyclo[2.2.2]octan-3-one;dihydrate;hydrochloride Chemical compound O.O.Cl.C1CC2CCN1C(=C)C2=O WGTNAUBLJLWMAP-UHFFFAOYSA-N 0.000 description 1
- INJXHKJCWKXDAE-UHFFFAOYSA-N 2H-thieno[2,3-b]pyridin-6-one Chemical group O=C1C=CC2=CCSC2=N1 INJXHKJCWKXDAE-UHFFFAOYSA-N 0.000 description 1
- ZEHZWIKRZOLNDL-UHFFFAOYSA-N 2h-thieno[2,3-c]pyridine-6-carboxylic acid Chemical compound OC(=O)N1C=CC2=CCSC2=C1 ZEHZWIKRZOLNDL-UHFFFAOYSA-N 0.000 description 1
- VGKLVWTVCUDISO-UHFFFAOYSA-N 3,4-dibromothiophene Chemical compound BrC1=CSC=C1Br VGKLVWTVCUDISO-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- SRWDQSRTOOMPMO-UHFFFAOYSA-N 3-bromo-1-benzothiophene Chemical compound C1=CC=C2C(Br)=CSC2=C1 SRWDQSRTOOMPMO-UHFFFAOYSA-N 0.000 description 1
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
- LXWLEQZDXOQZGW-UHFFFAOYSA-N 3-bromofuran Chemical compound BrC=1C=COC=1 LXWLEQZDXOQZGW-UHFFFAOYSA-N 0.000 description 1
- YDPLFBIGFQFIDB-UHFFFAOYSA-N 3-chloropyridine-2-carbonitrile Chemical compound ClC1=CC=CN=C1C#N YDPLFBIGFQFIDB-UHFFFAOYSA-N 0.000 description 1
- ZVGDKOQPJCOCLI-UHFFFAOYSA-N 3-chloropyridine-4-carbaldehyde Chemical compound ClC1=CN=CC=C1C=O ZVGDKOQPJCOCLI-UHFFFAOYSA-N 0.000 description 1
- QLILRKBRWXALIE-UHFFFAOYSA-N 3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1 QLILRKBRWXALIE-UHFFFAOYSA-N 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 1
- DYRMBQRXOMOMNW-UHFFFAOYSA-N 4-chloropyridine-3-carbaldehyde Chemical compound ClC1=CC=NC=C1C=O DYRMBQRXOMOMNW-UHFFFAOYSA-N 0.000 description 1
- XGAFCCUNHIMIRV-UHFFFAOYSA-N 4-chloropyridine;hydron;chloride Chemical compound Cl.ClC1=CC=NC=C1 XGAFCCUNHIMIRV-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical group CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- OBGLQHSGHQAMLV-UHFFFAOYSA-N 4-methyl-5-nitropyridine-2-carbaldehyde Chemical compound CC1=CC(C=O)=NC=C1[N+]([O-])=O OBGLQHSGHQAMLV-UHFFFAOYSA-N 0.000 description 1
- SDRZCVDIDNFMAD-UHFFFAOYSA-N 7-oxidothieno[2,3-b]pyridin-7-ium Chemical compound [O-][N+]1=CC=CC2=C1SC=C2 SDRZCVDIDNFMAD-UHFFFAOYSA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000350052 Daniellia ogea Species 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 description 1
- 101000658543 Escherichia coli Type I restriction enzyme EcoAI endonuclease subunit Proteins 0.000 description 1
- 101000658546 Escherichia coli Type I restriction enzyme EcoEI endonuclease subunit Proteins 0.000 description 1
- 101000658530 Escherichia coli Type I restriction enzyme EcoR124II endonuclease subunit Proteins 0.000 description 1
- 101000658540 Escherichia coli Type I restriction enzyme EcoprrI endonuclease subunit Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical group NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Chemical class 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 206010018762 Grunting Diseases 0.000 description 1
- 229920000084 Gum arabic Chemical class 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Chemical group 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000658548 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaIXP endonuclease subunit Proteins 0.000 description 1
- 101000658542 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIIP endonuclease subunit Proteins 0.000 description 1
- 101000658529 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIP endonuclease subunit Proteins 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical group CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical group CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 101001042773 Staphylococcus aureus (strain COL) Type I restriction enzyme SauCOLORF180P endonuclease subunit Proteins 0.000 description 1
- 101000838760 Staphylococcus aureus (strain MRSA252) Type I restriction enzyme SauMRSORF196P endonuclease subunit Proteins 0.000 description 1
- 101000838761 Staphylococcus aureus (strain MSSA476) Type I restriction enzyme SauMSSORF170P endonuclease subunit Proteins 0.000 description 1
- 101000838758 Staphylococcus aureus (strain MW2) Type I restriction enzyme SauMW2ORF169P endonuclease subunit Proteins 0.000 description 1
- 101001042566 Staphylococcus aureus (strain Mu50 / ATCC 700699) Type I restriction enzyme SauMu50ORF195P endonuclease subunit Proteins 0.000 description 1
- 101000838763 Staphylococcus aureus (strain N315) Type I restriction enzyme SauN315I endonuclease subunit Proteins 0.000 description 1
- 101000838759 Staphylococcus epidermidis (strain ATCC 35984 / RP62A) Type I restriction enzyme SepRPIP endonuclease subunit Proteins 0.000 description 1
- 101000838756 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) Type I restriction enzyme SsaAORF53P endonuclease subunit Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OQNIOUUSBNJXGH-UHFFFAOYSA-N [1]benzofuro[3,2-c]pyridine-3-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=C(C(=O)O)N=C2 OQNIOUUSBNJXGH-UHFFFAOYSA-N 0.000 description 1
- AVZOGKFKFRRPKN-UHFFFAOYSA-N [1]benzothiolo[3,2-c]pyridine-3-carboxylic acid Chemical compound S1C2=CC=CC=C2C2=C1C=C(C(=O)O)N=C2 AVZOGKFKFRRPKN-UHFFFAOYSA-N 0.000 description 1
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 description 1
- 239000000205 acacia gum Chemical class 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960000276 acetophenazine Drugs 0.000 description 1
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 108020000715 acetylcholine receptors Proteins 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229950009852 carfenazine Drugs 0.000 description 1
- TVPJGGZLZLUPOB-SPIKMXEPSA-N carphenazine maleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C12=CC(C(=O)CC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 TVPJGGZLZLUPOB-SPIKMXEPSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960001552 chlorprothixene Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- TUFGVZMNGTYAQD-UHFFFAOYSA-N comins' reagent Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=C(Cl)C=N1 TUFGVZMNGTYAQD-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- YTKRILODNOEEPX-NSCUHMNNSA-N crotyl chloride Chemical compound C\C=C\CCl YTKRILODNOEEPX-NSCUHMNNSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MKYNHKOAYQRSBD-UHFFFAOYSA-N dioxouranium;nitric acid Chemical compound O=[U]=O.O[N+]([O-])=O.O[N+]([O-])=O MKYNHKOAYQRSBD-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- PMIMPBYTPPRBGD-UHFFFAOYSA-N ethyl 2-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1Cl PMIMPBYTPPRBGD-UHFFFAOYSA-N 0.000 description 1
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- MWUNMDKVCFRJPU-UHFFFAOYSA-N ethyl thieno[2,3-c]pyridine-2-carboxylate Chemical compound C1=NC=C2SC(C(=O)OCC)=CC2=C1 MWUNMDKVCFRJPU-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- UUKNFBHTKFKPEH-UHFFFAOYSA-N furo[2,3-c]pyridin-5-ylmethanol Chemical compound C1=NC(CO)=CC2=C1OC=C2 UUKNFBHTKFKPEH-UHFFFAOYSA-N 0.000 description 1
- KKUIVASBGOEYGD-UHFFFAOYSA-N furo[2,3-c]pyridine-2-carbaldehyde Chemical compound C1=NC=C2OC(C=O)=CC2=C1 KKUIVASBGOEYGD-UHFFFAOYSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000008273 gelatin Chemical class 0.000 description 1
- 229920000159 gelatin Chemical class 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical class N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 238000009224 group psychotherapy Methods 0.000 description 1
- 229940095895 haldol Drugs 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical group OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical group C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical group CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- MXNIODZSMNMILW-UHFFFAOYSA-N methyl 2-acetamido-2-dimethoxyphosphorylacetate Chemical compound COC(=O)C(NC(C)=O)P(=O)(OC)OC MXNIODZSMNMILW-UHFFFAOYSA-N 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical compound COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- NNBQAZBSJUATDO-UHFFFAOYSA-N methyl 2-methoxy-2-(phenylmethoxycarbonylamino)acetate Chemical compound COC(=O)C(OC)NC(=O)OCC1=CC=CC=C1 NNBQAZBSJUATDO-UHFFFAOYSA-N 0.000 description 1
- FFHLOZJKPAWEAX-UHFFFAOYSA-N methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate Chemical compound C1=CN=C2C(N)=C(C(=O)OC)SC2=C1 FFHLOZJKPAWEAX-UHFFFAOYSA-N 0.000 description 1
- TWEQNZZOOFKOER-UHFFFAOYSA-N methyl 3-aminothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1N TWEQNZZOOFKOER-UHFFFAOYSA-N 0.000 description 1
- OZVQPMGJPOWPNI-UHFFFAOYSA-N methyl [1]benzofuro[3,2-c]pyridine-3-carboxylate Chemical compound O1C2=CC=CC=C2C2=C1C=C(C(=O)OC)N=C2 OZVQPMGJPOWPNI-UHFFFAOYSA-N 0.000 description 1
- RNBGAXVXEPGWIB-UHFFFAOYSA-N methyl [1]benzothiolo[3,2-c]pyridine-3-carboxylate Chemical compound S1C2=CC=CC=C2C2=C1C=C(C(=O)OC)N=C2 RNBGAXVXEPGWIB-UHFFFAOYSA-N 0.000 description 1
- SUHXBEISAFXKIN-UHFFFAOYSA-N methyl thieno[2,3-b]pyridine-2-carboxylate Chemical compound C1=CN=C2SC(C(=O)OC)=CC2=C1 SUHXBEISAFXKIN-UHFFFAOYSA-N 0.000 description 1
- UJWDXLCZHGRIDS-UHFFFAOYSA-N methyl thieno[2,3-c]pyridine-5-carboxylate Chemical compound C1=NC(C(=O)OC)=CC2=C1SC=C2 UJWDXLCZHGRIDS-UHFFFAOYSA-N 0.000 description 1
- QIDGNOLDYYRKHI-UHFFFAOYSA-N methyl thieno[3,2-b]pyridine-2-carboxylate Chemical compound C1=CC=C2SC(C(=O)OC)=CC2=N1 QIDGNOLDYYRKHI-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical group C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- QYQZCDBKJWOCGE-UHFFFAOYSA-N n-(2-methyl-1-azabicyclo[2.2.2]octan-3-ylidene)hydroxylamine;hydrochloride Chemical compound Cl.C1CC2CCN1C(C)C2=NO QYQZCDBKJWOCGE-UHFFFAOYSA-N 0.000 description 1
- QFBAIWVETQQJMF-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-2-(trifluoromethyl)furo[3,2-c]pyridine-6-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=C(C(F)(F)F)O2 QFBAIWVETQQJMF-VFZGTOFNSA-N 0.000 description 1
- BYXXHRLIIGIKHS-VFZGTOFNSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]-3-(trifluoromethyl)furo[2,3-c]pyridine-5-carboxamide Chemical compound C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2C(F)(F)F BYXXHRLIIGIKHS-VFZGTOFNSA-N 0.000 description 1
- MQUIWJKZMYUCHV-RZSRGUMRSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1OC=C2 MQUIWJKZMYUCHV-RZSRGUMRSA-N 0.000 description 1
- PMVFFVDMVHXKRF-RZSRGUMRSA-N n-[(2s,3r)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC2CCN1[C@@H](C)[C@@H]2NC(=O)C(N=C1)=CC2=C1C=CS2 PMVFFVDMVHXKRF-RZSRGUMRSA-N 0.000 description 1
- MCNCUNXFFXEARZ-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-chlorofuro[3,2-c]pyridine-6-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2C=C(Cl)OC2=C1 MCNCUNXFFXEARZ-LBPRGKRZSA-N 0.000 description 1
- CAISWDUMNFTYIT-UTLKBRERSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3,3-dimethyl-2h-furo[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OCC(C)(C)C2=C1 CAISWDUMNFTYIT-UTLKBRERSA-N 0.000 description 1
- MCFKPMVTHBYQRP-CKUXDGONSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-ethylfuro[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2OC=C(CC)C2=C1 MCFKPMVTHBYQRP-CKUXDGONSA-N 0.000 description 1
- KRXBETLATVVYCL-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-iodothieno[2,3-c]pyridine-5-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NC=C2SC=C(I)C2=C1 KRXBETLATVVYCL-ZDUSSCGKSA-N 0.000 description 1
- HDNYLRCTIAPHQO-SQKCAUCHSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[2,3-c]pyridine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.S1C2=CC=CC=C2C2=C1C=NC(C(N[C@@H]1C3CCN(CC3)C1)=O)=C2 HDNYLRCTIAPHQO-SQKCAUCHSA-N 0.000 description 1
- IXVDQMJJPAKIQK-SQKCAUCHSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1]benzothiolo[3,2-c]pyridine-3-carboxamide;dihydrochloride Chemical compound Cl.Cl.S1C2=CC=CC=C2C(C=N2)=C1C=C2C(=O)N[C@@H]1C(CC2)CCN2C1 IXVDQMJJPAKIQK-SQKCAUCHSA-N 0.000 description 1
- WDCJGTXNJRXGLG-YDALLXLXSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-b]pyridine-2-carboxamide;hydrochloride Chemical compound Cl.C1=CN=C2OC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 WDCJGTXNJRXGLG-YDALLXLXSA-N 0.000 description 1
- BCVPFWBLDNBXIZ-LTCKWSDVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=NC=C2OC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 BCVPFWBLDNBXIZ-LTCKWSDVSA-N 0.000 description 1
- USJDQOUQSDDWPO-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1OC=C2 USJDQOUQSDDWPO-GXKRWWSZSA-N 0.000 description 1
- OMRGYXZLDCEQNT-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furo[3,2-c]pyridine-6-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CO2 OMRGYXZLDCEQNT-GXKRWWSZSA-N 0.000 description 1
- VDBSXNXZYUJSSU-LTCKWSDVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=CN=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 VDBSXNXZYUJSSU-LTCKWSDVSA-N 0.000 description 1
- LUCHYNKYXTVXEW-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.N1=C2SC=CC2=CC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 LUCHYNKYXTVXEW-GXKRWWSZSA-N 0.000 description 1
- XBLCZLXVAZGAGA-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-b]pyridine-6-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=C2C=CSC2=NC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 XBLCZLXVAZGAGA-GXKRWWSZSA-N 0.000 description 1
- CAHJRPJEJDNZAB-LTCKWSDVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=NC=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 CAHJRPJEJDNZAB-LTCKWSDVSA-N 0.000 description 1
- BJPXADWQFUMLMW-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[2,3-c]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1SC=C2 BJPXADWQFUMLMW-GXKRWWSZSA-N 0.000 description 1
- FHQWTDOVYZRKCI-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-b]pyridine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1=C2SC=CC2=NC(C(N[C@@H]2C3CCN(CC3)C2)=O)=C1 FHQWTDOVYZRKCI-GXKRWWSZSA-N 0.000 description 1
- NRSQSZUDBNWUOY-LTCKWSDVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N1=CC=C2SC(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 NRSQSZUDBNWUOY-LTCKWSDVSA-N 0.000 description 1
- GOFNNDAVSYYGLF-GXKRWWSZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide;dihydrochloride Chemical compound Cl.Cl.N([C@@H]1C2CCN(CC2)C1)C(=O)C(N=C1)=CC2=C1C=CS2 GOFNNDAVSYYGLF-GXKRWWSZSA-N 0.000 description 1
- BCKKMCXDLFONPN-UQKRIMTDSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thieno[3,4-c]pyridine-6-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C2=CSC=C2C=NC=1C(=O)N[C@@H]1C(CC2)CCN2C1 BCKKMCXDLFONPN-UQKRIMTDSA-N 0.000 description 1
- ODXYAIIKLLODAU-UHFFFAOYSA-N n-octan-3-ylidenehydroxylamine Chemical compound CCCCCC(CC)=NO ODXYAIIKLLODAU-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- MOOYVEVEDVVKGD-UHFFFAOYSA-N oxaldehydic acid;hydrate Chemical compound O.OC(=O)C=O MOOYVEVEDVVKGD-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- XBLAYFVCUPTTOI-UHFFFAOYSA-N oxalic acid;thiophen-3-amine Chemical compound NC=1C=CSC=1.OC(=O)C(O)=O XBLAYFVCUPTTOI-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- UVBXZOISXNZBLY-UHFFFAOYSA-L palladium(2+);triphenylphosphane;diacetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UVBXZOISXNZBLY-UHFFFAOYSA-L 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000010254 physiological adaptation Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000768 polyamine Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 108020001213 potassium channel Chemical group 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 229940035004 seroquel Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000661 sodium alginate Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000009154 spontaneous behavior Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical class C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical compound C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 description 1
- XGCSHAYMNOFFNA-UHFFFAOYSA-N thieno[2,3-b]pyridine-2-carboxylic acid Chemical compound C1=CN=C2SC(C(=O)O)=CC2=C1 XGCSHAYMNOFFNA-UHFFFAOYSA-N 0.000 description 1
- IOVJNINZHOJSDD-UHFFFAOYSA-N thieno[2,3-b]pyridine-5-carbonitrile Chemical compound N#CC1=CN=C2SC=CC2=C1 IOVJNINZHOJSDD-UHFFFAOYSA-N 0.000 description 1
- JDWFURAFRCAVOH-UHFFFAOYSA-N thieno[2,3-b]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C2SC=CC2=C1 JDWFURAFRCAVOH-UHFFFAOYSA-N 0.000 description 1
- KTSOZLHVFLYDNN-UHFFFAOYSA-N thieno[2,3-b]pyridine-6-carbonitrile Chemical compound N#CC1=CC=C2C=CSC2=N1 KTSOZLHVFLYDNN-UHFFFAOYSA-N 0.000 description 1
- MVAMOERRWMZNPJ-UHFFFAOYSA-N thieno[2,3-c]pyridine-2-carboxamide Chemical compound C1=NC=C2SC(C(=O)N)=CC2=C1 MVAMOERRWMZNPJ-UHFFFAOYSA-N 0.000 description 1
- GHYPQAOXZUEFNP-UHFFFAOYSA-N thieno[2,3-c]pyridine-2-carboxylic acid Chemical compound C1=NC=C2SC(C(=O)O)=CC2=C1 GHYPQAOXZUEFNP-UHFFFAOYSA-N 0.000 description 1
- RIIAHEIBOHZBED-UHFFFAOYSA-N thieno[2,3-c]pyridine-5-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1SC=C2 RIIAHEIBOHZBED-UHFFFAOYSA-N 0.000 description 1
- WVWCTPQHJWMLKI-UHFFFAOYSA-N thieno[3,2-b]pyridine-2-carboxylic acid Chemical compound C1=CC=C2SC(C(=O)O)=CC2=N1 WVWCTPQHJWMLKI-UHFFFAOYSA-N 0.000 description 1
- DSARAHGYZHXMQZ-UHFFFAOYSA-N thieno[3,2-b]pyridine-5-carboxamide Chemical compound NC(=O)C1=CC=C2SC=CC2=N1 DSARAHGYZHXMQZ-UHFFFAOYSA-N 0.000 description 1
- CWBYTSQAVGCXFW-UHFFFAOYSA-N thieno[3,2-b]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2SC=CC2=N1 CWBYTSQAVGCXFW-UHFFFAOYSA-N 0.000 description 1
- QYCIXUKZMDUDBK-UHFFFAOYSA-N thieno[3,2-b]pyridine-6-carbonitrile Chemical compound N#CC1=CN=C2C=CSC2=C1 QYCIXUKZMDUDBK-UHFFFAOYSA-N 0.000 description 1
- WEYMRIJRWNCSFV-UHFFFAOYSA-N thieno[3,2-b]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN=C2C=CSC2=C1 WEYMRIJRWNCSFV-UHFFFAOYSA-N 0.000 description 1
- VKOINCMQZKBKHH-UHFFFAOYSA-N thieno[3,2-c]pyridine-2-carboxylic acid Chemical compound N1=CC=C2SC(C(=O)O)=CC2=C1 VKOINCMQZKBKHH-UHFFFAOYSA-N 0.000 description 1
- SJOJSVUJOMBMRX-UHFFFAOYSA-N thieno[3,2-c]pyridine-6-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC2=C1C=CS2 SJOJSVUJOMBMRX-UHFFFAOYSA-N 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 description 1
- WSEJZRIZDQWMKQ-UHFFFAOYSA-N thiophene-2,3-dicarbaldehyde Chemical compound O=CC=1C=CSC=1C=O WSEJZRIZDQWMKQ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 1
- ULYLMHUHFUQKOE-UHFFFAOYSA-N trimethyl(prop-2-ynyl)silane Chemical compound C[Si](C)(C)CC#C ULYLMHUHFUQKOE-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- 229940018503 zyban Drugs 0.000 description 1
- 229940039925 zyprexa Drugs 0.000 description 1
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29770901P | 2001-06-12 | 2001-06-12 | |
| US29770801P | 2001-06-12 | 2001-06-12 | |
| US29771001P | 2001-06-12 | 2001-06-12 | |
| US29771201P | 2001-06-12 | 2001-06-12 | |
| US29771101P | 2001-06-12 | 2001-06-12 | |
| US60/297,712 | 2001-06-12 | ||
| US60/297,709 | 2001-06-12 | ||
| US60/297,711 | 2001-06-12 | ||
| US60/297,710 | 2001-06-12 | ||
| US60/297,708 | 2001-06-12 | ||
| US32859601P | 2001-10-11 | 2001-10-11 | |
| US60/328,596 | 2001-10-11 | ||
| US37349502P | 2002-04-18 | 2002-04-18 | |
| US60/373,495 | 2002-04-18 | ||
| PCT/US2002/016568 WO2002100857A1 (en) | 2001-06-12 | 2002-06-06 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20040018266A true KR20040018266A (ko) | 2004-03-02 |
Family
ID=27569623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2003-7016210A Withdrawn KR20040018266A (ko) | 2001-06-12 | 2002-06-06 | 질환 치료용 퀴누클리딘 치환된 멀티시클릭 헤테로아릴 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7067515B2 (enExample) |
| EP (1) | EP1406901A1 (enExample) |
| JP (1) | JP2004537532A (enExample) |
| KR (1) | KR20040018266A (enExample) |
| CN (1) | CN1511154A (enExample) |
| AR (1) | AR036040A1 (enExample) |
| BR (1) | BR0210384A (enExample) |
| CA (1) | CA2445467A1 (enExample) |
| CO (1) | CO5540302A2 (enExample) |
| CZ (1) | CZ20033377A3 (enExample) |
| EA (1) | EA200301216A1 (enExample) |
| IL (1) | IL159344A0 (enExample) |
| MX (1) | MXPA03011484A (enExample) |
| NO (1) | NO20035522D0 (enExample) |
| PE (1) | PE20030431A1 (enExample) |
| PL (1) | PL367311A1 (enExample) |
| WO (1) | WO2002100857A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6911543B2 (en) * | 2001-10-02 | 2005-06-28 | Pfizer Inc. | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| DE10164139A1 (de) * | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US7977485B2 (en) | 2002-06-10 | 2011-07-12 | Bayer Schering Pharma Aktiengesellshaft | 2-heteroaryl carboxamides |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| CA2499128C (en) | 2002-09-25 | 2012-07-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| WO2004039366A1 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| CA2503786A1 (en) * | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Compounds having both alpha7 nicotinic agonist activity and 5ht, antagonist activity for treatment of cns diseases |
| OA12968A (en) * | 2002-12-06 | 2006-10-13 | Pharmacia & Upjohn Co Llc | Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof. |
| JP4598674B2 (ja) * | 2003-01-08 | 2010-12-15 | 田辺三菱製薬株式会社 | 統合失調症治療剤 |
| EP1587511A2 (en) * | 2003-01-22 | 2005-10-26 | Pharmacia & Upjohn Company LLC | Treatment of diseases with alpha-7 nach receptor full agonists |
| DE10334724A1 (de) * | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-Biarylamide |
| US7396833B2 (en) | 2003-12-22 | 2008-07-08 | Memory Pharmaceuticals Corporation | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
| EP1699488A2 (en) * | 2003-12-23 | 2006-09-13 | Pfizer Products Incorporated | Therapeutic combination for cognition enhancement and psychotic disorders |
| US20050171079A1 (en) * | 2004-02-04 | 2005-08-04 | Schrimpf Michael R. | Amino-substituted tricyclic derivatives and methods of use |
| US7365193B2 (en) | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
| CN103724343A (zh) | 2004-03-25 | 2014-04-16 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
| CA2567977A1 (en) | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| KR20070015607A (ko) | 2004-05-07 | 2007-02-05 | 메모리 파마슈티칼스 코포레이션 | 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도 |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0424564D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| WO2006069097A2 (en) | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| WO2007027855A2 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| WO2007038367A1 (en) * | 2005-09-23 | 2007-04-05 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| RU2008139599A (ru) | 2006-03-07 | 2010-04-20 | Эррэй Биофарма Инк. (Us) | Гетеробициклические производные пиразола и способы их применения |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| US8697722B2 (en) * | 2007-11-02 | 2014-04-15 | Sri International | Nicotinic acetylcholine receptor modulators |
| SI2889033T1 (en) | 2008-11-19 | 2018-08-31 | Forum Pharmaceuticals Inc. | Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| WO2010132423A1 (en) * | 2009-05-11 | 2010-11-18 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors |
| WO2011020712A2 (en) * | 2009-08-18 | 2011-02-24 | Universite Libre De Bruxelles | Oligothiophenes derivatives |
| US8431595B2 (en) | 2009-08-20 | 2013-04-30 | The University Of Tennessee Research Foundation | Furanopyridine cannabinoid compounds and related methods of use |
| EP2523562B1 (en) * | 2010-01-11 | 2019-01-02 | Astraea Therapeutics, LLC | Nicotinic acetylcholine receptor modulators |
| GB201002563D0 (en) | 2010-02-15 | 2010-03-31 | Cambridge Entpr Ltd | Compounds |
| CN103221411B (zh) | 2010-05-17 | 2016-05-11 | 富瑞姆制药公司 | (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型 |
| KR101928505B1 (ko) * | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
| EP2727604A4 (en) | 2011-06-30 | 2015-03-18 | Toray Industries | ANTIPRURIGINOUS AGENT |
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| KR101684955B1 (ko) * | 2012-07-23 | 2016-12-12 | 주식회사유한양행 | 퓨란-함유 융합 고리 화합물 또는 그의 염 및 이를 포함하는 약학 조성물 |
| JP6359940B2 (ja) * | 2014-10-14 | 2018-07-18 | 国立大学法人 名古屋工業大学 | ジフルオロメチルアセチレン化合物類及びその製造方法 |
| CN106883270B (zh) | 2015-11-26 | 2019-03-26 | 财团法人工业技术研究院 | 有机金属化合物、包含其的有机发光装置 |
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| CN115974833B (zh) * | 2022-12-28 | 2024-08-02 | 苏州汉德创宏生化科技有限公司 | 一种3-氨基噻吩草酸盐的制备方法 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ194747A (en) | 1979-08-29 | 1988-11-29 | Schering Ag | 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives |
| ZA832549B (en) | 1982-04-14 | 1988-09-28 | Beecham Group Plc | Pharmaceutically active compounds |
| FI74707C (fi) | 1982-06-29 | 1988-03-10 | Sandoz Ag | Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror. |
| DE3429830A1 (de) | 1983-08-26 | 1985-03-07 | Sandoz-Patent-GmbH, 7850 Lörrach | Automatische carbonsaeure- und sulfonsaeureester oder -amide |
| US5175173A (en) | 1983-12-22 | 1992-12-29 | Sun Jung Hui | Carboxamides useful as antiemetic or antipsychotic agents |
| US4888353A (en) | 1986-02-28 | 1989-12-19 | Erbamont, Inc. | Carboxamides useful as antiemetic or antipsychotic agents |
| DE3445377A1 (de) | 1983-12-23 | 1985-07-04 | Sandoz-Patent-GmbH, 7850 Lörrach | Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen |
| EP0385517B1 (en) | 1985-03-14 | 1993-04-14 | BEECHAM GROUP plc | Medicaments for the treatment of emesis |
| US4937247A (en) | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
| GB8520616D0 (en) | 1985-08-16 | 1985-09-25 | Beecham Group Plc | Compounds |
| US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| DE3782107T2 (de) | 1986-07-25 | 1993-04-01 | Beecham Group Plc | Azabicyclische verbindungen, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung. |
| HU202108B (en) | 1986-07-30 | 1991-02-28 | Sandoz Ag | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol |
| EP0278173B1 (en) | 1986-12-17 | 1993-11-03 | Glaxo Group Limited | Use of heterocyclic derivatives in the treatment of depressions |
| EP0559297B1 (en) | 1986-12-17 | 1997-05-07 | Glaxo Group Limited | Use of heterocyclic derivatives for the manufacture of medicaments |
| GB8806990D0 (en) | 1988-03-23 | 1988-04-27 | Beecham Group Plc | Novel compounds |
| US5322951A (en) | 1987-01-05 | 1994-06-21 | Beecham Group, P.L.C. | Certain 1-(2,3-dihydro-indole)carbonyl intermediates |
| GB8701022D0 (en) | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
| US4835162A (en) | 1987-02-12 | 1989-05-30 | Abood Leo G | Agonists and antagonists to nicotine as smoking deterents |
| DE3852145T2 (de) | 1987-02-18 | 1995-04-06 | Beecham Group Plc | Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten. |
| DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US4921982A (en) | 1988-07-21 | 1990-05-01 | Eli Lilly And Company | 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists |
| NZ227229A (en) | 1987-12-10 | 1991-03-26 | Duphar Int Res | Indole derivatives and pharmaceutical compositions |
| IE63474B1 (en) | 1987-12-24 | 1995-04-19 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| US4863919A (en) | 1988-02-01 | 1989-09-05 | A. H. Robins Company, Incorporated | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes |
| US4924010A (en) | 1988-02-04 | 1990-05-08 | Rorer Pharmaceutical Corporation | Benzoxepins as intermediates to 5HT3 antagonists |
| DE3810552A1 (de) | 1988-03-29 | 1989-10-19 | Sandoz Ag | Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben |
| US5246942A (en) | 1988-04-27 | 1993-09-21 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration |
| US4863921A (en) | 1988-04-27 | 1989-09-05 | Rorer Pharmaceutical Corporation | Dibenzofurancarboxamides and their pharmaceutical compositions and methods |
| US4920227A (en) | 1988-11-29 | 1990-04-24 | Rorer Pharmaceutical Corp. | Benzobicyclic carboxamide 5-HT3 antagonists |
| US4920219A (en) | 1988-11-29 | 1990-04-24 | Rorer Pharmaceutical Corp. | Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents |
| US4933445A (en) | 1988-11-29 | 1990-06-12 | Rorer Pharmaceutical Corporation | Heteroazabenzobicyclic carboxamide 5-HT3 antagonists |
| WO1990014347A1 (fr) | 1989-05-24 | 1990-11-29 | Nippon Shinyaku Co., Ltd. | Derives d'indole et medicament |
| EP0402056A3 (en) | 1989-06-06 | 1991-09-04 | Beecham Group p.l.c. | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| US4935511A (en) | 1989-09-26 | 1990-06-19 | Rorer Pharmaceutical Corporation | Benzoxazine and benzoxazepine carboxamide 5-HT3 antagonists |
| GB2236751B (en) | 1989-10-14 | 1993-04-28 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| GB8928837D0 (en) | 1989-12-21 | 1990-02-28 | Beecham Group Plc | Pharmaceuticals |
| EP0436245A1 (en) | 1989-12-27 | 1991-07-10 | Duphar International Research B.V | Substituted 3,4-annelated benzimidazol-2(1H)-ones |
| GB9009542D0 (en) | 1990-04-27 | 1990-06-20 | Beecham Group Plc | Novel compounds |
| AU7618991A (en) | 1990-05-14 | 1991-11-14 | Syntex (U.S.A.) Inc. | Novel tricyclic compounds |
| AU8405891A (en) | 1990-08-31 | 1992-03-30 | Nippon Shinyaku Co. Ltd. | Indole derivative and medicine |
| US5200415A (en) * | 1990-11-01 | 1993-04-06 | Asahi Kasei Kogyo Kabushiki Kaisha | Pyrazolo[1,5-a]pyridine-3-carboxylic acid derivatives and their pharmaceutical use |
| US5189041A (en) | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
| GB9027098D0 (en) | 1990-12-13 | 1991-02-06 | Beecham Group Plc | Pharmaceuticals |
| HU211081B (en) | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
| IL100432A (en) | 1990-12-27 | 1996-01-19 | Erba Carlo Spa | Dihydrobenzofuran carboxamide derivatives their preparation and pharmaceutical compositions containing them |
| US5114947A (en) | 1990-12-27 | 1992-05-19 | Erbamont Inc. | Method for alleviating anxiety using benzobicyclic carboxamides |
| GB9028105D0 (en) | 1990-12-27 | 1991-02-13 | Erba Carlo Spa | Process for the preparation of substituted benzofuran derivatives |
| US5260303A (en) | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
| DE4115215A1 (de) | 1991-05-10 | 1992-11-12 | Merck Patent Gmbh | Indolderivate |
| GB9120628D0 (en) | 1991-09-27 | 1991-11-06 | Fujisawa Pharmaceutical Co | Pyrrolobenzoxazine derivatives and process for preparation thereof |
| WO1993009116A1 (fr) * | 1991-11-07 | 1993-05-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose a base de quinuclidine et utilisation dudit compose en medecine |
| JPH05310732A (ja) | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−３−カルボン酸誘導体 |
| JP2699794B2 (ja) | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔３，２−ｂ〕ピリジン誘導体 |
| US5273972A (en) | 1992-03-26 | 1993-12-28 | A. H. Robins Company, Incorporated | [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates |
| EP0635508B1 (en) * | 1992-04-10 | 1999-10-06 | Asahi Kasei Kogyo Kabushiki Kaisha | Tetrahydropyridine derivative having substituents on three rings |
| SE9201478D0 (sv) | 1992-05-11 | 1992-05-11 | Kabi Pharmacia Ab | Heteroaromatic quinuclidinenes, their use and preparation |
| US5300512A (en) | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
| US5977144A (en) | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| IT1265057B1 (it) * | 1993-08-05 | 1996-10-28 | Dompe Spa | Tropil 7-azaindolil-3-carbossiamidi |
| GB9406857D0 (en) | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5510478A (en) | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| GB9507882D0 (en) | 1995-04-18 | 1995-05-31 | Pharmacia Spa | Substituted dihydrobenzofuran derivatives as 5-ht4 agonists |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| ES2109190B1 (es) * | 1996-03-22 | 1998-07-01 | Univ Madrid Complutense | Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht |
| FR2769915B1 (fr) | 1997-10-21 | 2000-10-13 | Synthelabo | Derives d'indazole tricycliques, leur preparation et leur application en therapeutique |
| JP2003501022A (ja) | 1999-05-27 | 2003-01-14 | ファルマシア・アンド・アップジョン・カンパニー | イオンチャネルコンダクタンスを測定するための方法およびその組成物 |
| SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| JP4616971B2 (ja) | 2000-07-18 | 2011-01-19 | 田辺三菱製薬株式会社 | １−アザビシクロアルカン化合物およびその医薬用途 |
| US20020016334A1 (en) | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
| US6911543B2 (en) * | 2001-10-02 | 2005-06-28 | Pfizer Inc. | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
| ES2348282T3 (es) | 2002-04-18 | 2010-12-02 | Astrazeneca Ab | Compuestos de tienilo. |
| MXPA04010191A (es) | 2002-04-18 | 2005-02-03 | Astrazeneca Ab | Compuestos de furilo. |
| BR0309345A (pt) | 2002-04-18 | 2005-02-15 | Astrazeneca Ab | Composto ou sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou de distúrbios de dano intelectual, e de jetlag, interrupção do hábito de fumar, dependência de nicotina, ânsias, dor e colite ulcerativa |
-
2002
- 2002-05-30 AR ARP020102020A patent/AR036040A1/es unknown
- 2002-06-05 PE PE2002000470A patent/PE20030431A1/es not_active Application Discontinuation
- 2002-06-06 IL IL15934402A patent/IL159344A0/xx unknown
- 2002-06-06 KR KR10-2003-7016210A patent/KR20040018266A/ko not_active Withdrawn
- 2002-06-06 CA CA002445467A patent/CA2445467A1/en not_active Abandoned
- 2002-06-06 CN CNA028098145A patent/CN1511154A/zh active Pending
- 2002-06-06 WO PCT/US2002/016568 patent/WO2002100857A1/en not_active Ceased
- 2002-06-06 EP EP02778932A patent/EP1406901A1/en not_active Withdrawn
- 2002-06-06 CZ CZ20033377A patent/CZ20033377A3/cs unknown
- 2002-06-06 BR BR0210384-2A patent/BR0210384A/pt not_active IP Right Cessation
- 2002-06-06 JP JP2003503624A patent/JP2004537532A/ja not_active Withdrawn
- 2002-06-06 PL PL02367311A patent/PL367311A1/xx not_active Application Discontinuation
- 2002-06-06 EA EA200301216A patent/EA200301216A1/ru unknown
- 2002-06-06 MX MXPA03011484A patent/MXPA03011484A/es unknown
- 2002-06-06 US US10/163,564 patent/US7067515B2/en not_active Expired - Fee Related
-
2003
- 2003-12-10 CO CO03108314A patent/CO5540302A2/es not_active Application Discontinuation
- 2003-12-11 NO NO20035522A patent/NO20035522D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2445467A1 (en) | 2002-12-19 |
| CZ20033377A3 (cs) | 2004-11-10 |
| NO20035522D0 (no) | 2003-12-11 |
| WO2002100857A1 (en) | 2002-12-19 |
| PE20030431A1 (es) | 2003-05-26 |
| PL367311A1 (en) | 2005-02-21 |
| EP1406901A1 (en) | 2004-04-14 |
| US7067515B2 (en) | 2006-06-27 |
| IL159344A0 (en) | 2004-06-01 |
| AR036040A1 (es) | 2004-08-04 |
| EA200301216A1 (ru) | 2004-06-24 |
| US20030045540A1 (en) | 2003-03-06 |
| MXPA03011484A (es) | 2004-03-18 |
| CN1511154A (zh) | 2004-07-07 |
| BR0210384A (pt) | 2004-06-29 |
| CO5540302A2 (es) | 2005-07-29 |
| JP2004537532A (ja) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20040018266A (ko) | 질환 치료용 퀴누클리딘 치환된 멀티시클릭 헤테로아릴 | |
| KR100614900B1 (ko) | 질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물 | |
| EP1425286B1 (en) | Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases | |
| WO2003070732A1 (en) | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease | |
| JP2004534065A (ja) | 疾患治療用のキヌクリジン置換二環系へテロ芳香族化合物 | |
| JP2006506395A (ja) | ＣＮＳ疾患の治療のための、α７ニコチンアゴニスト活性及び５ＨＴ３アンタゴニスト活性を有する化合物 | |
| JP2005511574A (ja) | Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド | |
| JP2005511574A6 (ja) | Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド | |
| US20050165047A1 (en) | Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof | |
| AU2002348498A1 (en) | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | |
| AU2002339957A1 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| UA77447C2 (en) | Azabicyclic-substituted fused heteroaryls, a pharmaceutical composition based thereon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20031211 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |